Clinical Trial

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-07-01; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT04008121
Lead Sponsor MediBeacon
Conditions Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Enrollment 10 participants
Start Date 2025-11-06
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-04